EE
Therapeutic Areas
TikoMed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ILB® for ALS | Amyotrophic Lateral Sclerosis | Phase 2 |
| ILB® for Myocardial Infarction | Heart Attack | Pre-clinical / Planning |
Leadership Team at TikoMed
BP
Björn Pilström
Chief Executive Officer & Chief Medical Officer
HO
Henrik Otendal
Chief Financial Officer
AW
Anita Westin Tocaj
Head of Regulatory Affairs
AB
Antonio Bermejo Gomez
Head of CMC
JO
Johan Olsson
Head of Accounting
SD
Staffan Dahlgren
Head of Drug Safety